BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9815961)

  • 1. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.
    Kurzman ID; MacEwen EG; Rosenthal RC; Fox LE; Keller ET; Helfand SC; Vail DM; Dubielzig RR; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Dec; 1(12):1595-601. PubMed ID: 9815961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.
    MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J
    J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
    Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
    Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
    MacEwen EG; Kurzman ID; Rosenthal RC; Smith BW; Manley PA; Roush JK; Howard PE
    J Natl Cancer Inst; 1989 Jun; 81(12):935-8. PubMed ID: 2733037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
    Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
    Kleinerman ES; Snyder JS; Jaffe N
    J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
    Meyers PA; Chou AJ
    Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
    Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
    Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
    Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
    Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.
    Meyers PA
    Adv Exp Med Biol; 2020; 1257():133-139. PubMed ID: 32483736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canine osteosarcoma: amputation and chemoimmunotherapy.
    MacEwen EG; Kurzman ID
    Vet Clin North Am Small Anim Pract; 1996 Jan; 26(1):123-33. PubMed ID: 8825571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.
    Vail DM; Kurzman ID; Glawe PC; O'Brien MG; Chun R; Garrett LD; Obradovich JE; Fred RM; Khanna C; Colbern GT; Working PK
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):131-6. PubMed ID: 12172978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
    Shi F; MacEwen EG; Kurzman ID
    Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.